Anavex Life Sciences Stock Is Deeply Oversold. Should You Buy the Dip?

What: Anavex Life Sciences stock has fallen **-35%** in the past month, with a current price of **$5.23**.
Why: Investors are selling due to concerns over the company's pipeline and clinical trial delays.
Signal: The stock's RSI has dropped to **20**, indicating a potential oversold condition.
Target: Analysts predict a potential rebound to **$7.50** within the next quarter.
Risk: Investors should be cautious due to the company's high debt-to-equity ratio of **2.5**.